News stories about Crispr Therapeutics (NASDAQ:CRSP) have been trending somewhat positive this week, according to Accern. The research firm scores the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Crispr Therapeutics earned a media sentiment score of 0.09 on Accern’s scale. Accern also gave news articles about the company an impact score of 46.7721044802528 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Shares of Crispr Therapeutics (CRSP) opened at $40.21 on Thursday. Crispr Therapeutics has a fifty-two week low of $11.63 and a fifty-two week high of $45.00. The firm has a market capitalization of $1,850.00 and a P/E ratio of -125.66.
A number of equities research analysts have issued reports on the company. Zacks Investment Research downgraded Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, January 25th. BidaskClub upgraded Crispr Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 25th. SunTrust Banks upgraded Crispr Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, January 23rd. Piper Jaffray Companies restated a “buy” rating and set a $22.75 price objective (down from $39.00) on shares of Crispr Therapeutics in a research report on Wednesday, January 10th. Finally, Oppenheimer restated a “hold” rating on shares of Crispr Therapeutics in a research report on Thursday, December 21st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. Crispr Therapeutics currently has an average rating of “Buy” and an average price target of $22.81.
In other Crispr Therapeutics news, Director Thomas Woiwode sold 1,700 shares of the firm’s stock in a transaction on Friday, November 24th. The stock was sold at an average price of $20.21, for a total transaction of $34,357.00. Following the transaction, the director now directly owns 8,218 shares in the company, valued at approximately $166,085.78. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Aktiengesellschaft Bayer acquired 527,472 shares of Crispr Therapeutics stock in a transaction on Friday, January 5th. The shares were purchased at an average price of $22.75 per share, for a total transaction of $11,999,988.00. The disclosure for this purchase can be found here. Over the last quarter, insiders sold 2,025,450 shares of company stock worth $40,556,705. Company insiders own 39.98% of the company’s stock.
WARNING: This story was posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at https://www.thelincolnianonline.com/2018/02/15/crispr-therapeutics-crsp-receives-daily-media-sentiment-rating-of-0-09.html.
Crispr Therapeutics Company Profile
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.